The financials
Zymeworks Inc. by the numbers
Zymeworks Inc. (ZYME) reported revenue of $2.4M in Q1 2026 (quarter ended Mar 31, 2026), down 91% from the same quarter a year earlier. That came with net loss of $44M. For the full year FY2025, revenue was $106M (+39% year on year) and net income −$81M. Its largest product in Jun 2026 was Royalty at $1.6M, 59% of the disclosed total, well ahead of Drug Supply For Ongoing Studies at 29%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $2.4M | $27M | −91% |
| Operating income | −$47M | −$26M | n/a |
| Net income | −$44M | −$23M | n/a |
| Diluted EPS | −$0.59 | −$0.30 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Royalty | $1.6M | 59% |
| Drug Supply For Ongoing Studies | $791K | 29% |
| Research Support Payments And Other Service | $291K | 11% |
| Drug Supply | $45K | 1.7% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $2.7M (+24%)
Royalty grew +189% year on yearRecognition Of Deferred -100% year on year
Segment Latestquarter on quarteryear on year
- Royalty$1.6M$1.6MQoQ +19%year on year +189%+19%+189%
- Drug Supply For Ongoing Studies$791.0K$791.0KQoQ +129%year on year -57%+129%-57%
- Research Support Payments And Other Service$291.0K$291.0KQoQ -26%year on year -39%-26%-39%
- Drug Supply$45.0K$45.0KQoQ -62%year on year --62%-
- Milestone$0.00$0.00QoQ -year on year -100%--100%
- Option Exercise Fee$0.00$0.00QoQ -year on year -100%--100%
- Recognition Of Deferred$0.00$0.00QoQ -year on year -100%--100%